|
|
From Pre-Emptive to Salvage Antifungal Therapy: Achieving Successful Outcomes
|
Release Date: October 10, 2009
Credit Expiration Date: October 10, 2010
|
Credit Hours
Physician CME: 1.0
Pharmacist CPE: 1.0 (0.10 CEUs)
|
|
Activity Type
Knowledge-based and competence-based
|
Educational Overview
When it comes to the management of invasive fungal infections (IFIs), a great deal of progress has
been made with significant advancements in prevention, diagnosis, and treatment. Promising new
clinical data allow for more targeted antifungal prophylaxis, identifying at-risk patients who
would benefit most from this strategy. Evolving radiographic and serologic diagnostic techniques
enable clinicians to initiate therapy at the time when therapeutic intervention is most effective.
More options when determining treatment lead to better health outcomes for more patients at risk
of or who have IFIs.
Today’s healthcare teams are more vigilant in anticipating the possibility of a fungal
infection. As a result, survival rates continue to increase while health outcomes improve.
These positive efforts must continue. Clinicians, who acquire a level of knowledge and
familiarity with new prevention approaches, diagnostic techniques, and management strategies
for IFIs, will be empowered to make timely, accurate, evidence-based decisions that benefit
their patients.
|
Target Audience
This activity has been developed for clinical pharmacists, infectious diseases physicians,
hematologists/oncologists, and transplant physicians responsible for the management of IFIs.
|
Purpose Statement
The purpose of this activity is to educate physicians and pharmacists involved in the management
of patients at risk of invasive fungal infections (IFIs) on treatment of IFIs. With this
knowledge, healthcare professionals will be able to select appropriate antifungal therapy
at various stages of infection from pre-emptive to salvage therapy.
|
Learning Objectives
At the conclusion of this activity, learners should be able to
- Distinguish between the advantages of a pre-emptive strategy and empiric treatment when managing patients with IFIs
- Identify the causes of treatment failure and recognize options for salvage therapy
|
Faculty
John R. Perfect, MD
Professor of Medicine
Chief, Division of Infectious Diseases
Duke University Medical Center
Durham, NC
Elizabeth S. Dodds Ashley, PharmD, MHS, BCPS
Infectious Diseases Clinical Pharmacist
University of Rochester Medical Center
Rochester, NY
|
Accreditation
Physicians
Accreditation Statement: This activity has been planned and implemented in accordance with the
Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
through joint sponsorship of Center for Independent Healthcare Education (Center) and Vemco MedEd.
Center is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: Center designates for this activity a maximum of 1.0 AMA PRA Category 1 Credit™
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacists
Accreditation Statement:
Center for Independent Healthcare Education (Center) is accredited by the
Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation: Center has assigned 1.0 contact hour (0.1 CEUs) of continuing pharmacy education
credit for participation in this activity.
ACPE Universal Activity Number: 0473-9999-09-015-H01-P
Estimated time to complete activity: 1 hour
|
Method of Participation and Instruction for Credit
- Review the entire CME/CE information including target audience, learning objectives, and disclosures.
- Review this activity in its entirety.
- Complete the Post Test, Evaluation, and Credit Application form.
- Mail the completed Post Test, Evaluation, and Credit Application form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 Or Fax to (908) 450-3300.
Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and Credit Application form.
|
Disclosure of Conflicts of Interest
Center for Independent Healthcare Education requires faculty, planners, and others who are in a position
to control the content of continuing education activities to disclose to the audience any real or apparent
conflict of interest related to the activity. All identified conflicts of interest are reviewed to ensure
fair balance, objectivity, and scientific rigor in all activities. The faculty is further required to
disclose discussion of off-label uses in their presentations.
|
Disclosure
Faculty
John R. Perfect, MD
Grant/Research Support: Enzon, Pfizer, Schering-Plough, Merck, and Astellas
Advisor/Consultant: Enzon, Pfizer, Schering-Plough, Astellas, and Merck
Elizabeth S. Dodds Ashley, PharmD, MHS, BCPS
Grant/Research Support: Astellas and Schering-Plough
Advisory Boards: Astellas
Promotional Speakers Bureau: Schering-Plough and Merck
Planning Committee Members
Employees of Center for Independent Healthcare Education and Vemco MedEd have no relevant financial
relationships to disclose.
Off-label Disclosure Statement
During this activity, off-label use of the following antifungal agents will be discussed: fluconazole
(for empiric therapy in febrile neutropenic patients), itraconazole (for empiric therapy in febrile
neutropenic patients), voriconazole (for empiric therapy in febrile neutropenic patients and for
refractory infections caused by Aspergillus, Candida, and Cryptococcus); caspofungin (for refractory
infections caused by Candida); posaconazole (for refractory infections caused by Aspergillus, Fusarium,
and Cryptococcus); liposomal amphotericin B (at a dose of 10 mg/kg); voriconazole/caspofungin
combination therapy (for treatment of invasive aspergillosis).
|
Joint Sponsorship
This activity is jointly sponsored by Center for Independent Healthcare Education and Vemco MedEd.
|
Commercial Support
This activity is supported by an educational grant from Schering-Plough Corporation.
|
Fee
There is no fee associated with this activity.
|
Hardware/Software Requirements
Web Browser
Internet Explorer or Mozilla
Note: Please disable any “pop-up blocker” features.
Software
Adobe Acrobat Reader version 4 or above to view PDF files (If you do not have Acrobat Reader, you can download it
for free from http://get.adobe.com/reader)
Connection Speed
Cable, DSL, or better of at least 300 kbps
Hardware
PC or Apple
System Check
Please e-mail any questions or concerns to info@vemcomeded.com.
|
Copyright Statement
Copyright © 2009 Vemco MedEd, LLC. All Rights Reserved.
Permission for accreditation use granted to Center for Independent Healthcare Education.
|
Disclaimer
The opinions expressed in this educational activity are those of the faculty and do not reflect the views of
Center for Independent Healthcare Education (Center) and Vemco MedEd. This educational activity may discuss
off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been
approved by the United States Food and Drug Administration (FDA). Center and Vemco MedEd do not recommend the
use of any product/procedure outside of the labeled indications. A qualified healthcare professional should be
consulted before using any therapeutic product/procedure discussed. Clinicians should verify all information and
data before treating patients or employing any therapies described in this continuing education activity. Please
refer to the prescribing information for each product/procedure for approved
indication, contraindications, and warnings.
|
Privacy Policy
http://www.vemcomeded.com/privacy.asp
|
Contact Information
For questions regarding the accreditation of this activity, please contact Center for Independent Healthcare
Education at info@jointsponsor.com
|
Start Activity
|
|
|
|
|